Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
postMONARCH: Abemaciclib plus Fulvestrant in Advanced Breast Cancer
NCT05169567Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Arm A: Abemaciclib plus Fulvestrant with Arm B: Placebo plus Fulvestrant (2 arms). Primary endpoint: Progression-Free Survival at 21 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05169567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169567.